ARS Pharmaceuticals (SPRY) Assets Average (2021 - 2026)

ARS Pharmaceuticals has disclosed Assets Average across 6 years of filings, most recently posting $307.6 million for Q1 2026.

• Assets Average for Q1 2026 came in at $307.6 million, down 9.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $307.6 million (down 9.32% YoY), and the FY2025 annual result was $339.4 million, up 16.17% from the prior year.
• Assets Average came in at $307.6 million for Q1 2026 at ARS Pharmaceuticals, down from $350.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $350.2 million in Q4 2025 to a low of $187.0 million in Q1 2022.
• The 5-year median for Assets Average is $276.3 million (2023), against an average of $276.7 million.
• Across the five-year window, Assets Average tumbled 51.88% in 2022 and jumped 56.13% in 2025, its largest moves.
• ARS Pharmaceuticals' Assets Average stood at $276.2 million in 2022, then dropped by 12.81% to $240.9 million in 2023, then increased by 18.06% to $284.4 million in 2024, then climbed by 23.16% to $350.2 million in 2025, then decreased by 12.17% to $307.6 million in 2026.
• The last three Assets Average figures came in at $307.6 million (Q1 2026), $350.2 million (Q4 2025), and $343.1 million (Q3 2025), per Business Quant data.